Safety and Tolerability of the D1 Dopamine Receptor Antagonist Ecopipam in Patients With Lesch-Nyhan Disease

Key facts

Sponsor

Psyadon Pharma

Principal Investigator

Hyder A Jinnah, MD

Emory University

Intervention

Ecopipam(drug)

Enrollment

5 enrolled

Eligibility

6-65 years · MALE

Timeline

2010 – 2011

Study locations (2)

• University of California at San Diego, San Diego, California, United States
• Emory Univesity, Atlanta, Georgia, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Disorder of purine metabolism

Additional recruiting or active studies for the same condition.

• RECRUITINGEARLY PHASE1NCT06612411
  B.Subtilis Attenuate Symptoms in Diarrhea-predominant Irritable Bowel Syndrome by Increasing Hypoxanthine Biosynthesis
  Jinling Hospital, China

See all trials for Disorder of purine metabolism →